AMENDMENTS TO THE CLAIMS:

The following is a complete listing of the claims and reflects all changes currently being made to the claims. This listing supersedes all earlier versions and all earlier listings of the claims.

1. (Currently Amended): A texture masking oral dosage form comprising:

(a) a unitary soft core comprising a plurality of active agent particles having an average size of from about 150 μm to about 500 μm ~~greater than about 50 μm~~, a hydrocolloid, and water; and

(b) a brittle shell encasing the soft core in an amount of from about 20% to about 50% of the total weight of the texture masking oral dosage form and a thickness of from about 500 μm to about 3000 μm, wherein the weight ratio of active agent particles to shell is from about 1.0:0.5 to about 1.0:15 in the texture masking oral dosage form.

2. (Previously Presented): An oral dosage form of claim 1, wherein the weight ratio of active agent particles to shell is from about 1.0:2 to about 1.0:12.

3. (Previously Presented): An oral dosage form of claim 2, wherein the weight ratio of particles to shell is from about 1.0:4 to about 1.0:9.

4. (Original): An oral dosage form of claim 1, wherein the soft core is pectin based.

5. (Previously Presented): An oral dosage form of claim 1, wherein the soft core is gelatin based.

6. (Previously Presented): An oral dosage form of claim 1, wherein the soft core has a hardness of about 1 to about 8 kp/cm^2.

7. (Previously Presented): An oral dosage form of claim 1, wherein the active agent is selected from the group consisting of acetaminophen, ibuprofen, pseudoephedrine, dextromethorphan, diphenhydramine, chlorpheniramine, calcium carbonate, magnesium

hydroxide, magnesium carbonate, magnesium oxide, aluminum hydroxide, mixtures thereof, and pharmaceutically acceptable salts thereof.

8. (Original): An oral dosage form of claim 7, wherein the active agent is acetaminophen or ibuprofen.

9. (Original): An oral dosage form of claim 8, wherein the active agent is acetaminophen.

10. (Previously Presented): An oral dosage form of claim 8, wherein the active agent is ibuprofen.

11. (Previously Presented): An oral dosage form of claim 3, wherein the active agent is selected from the group consisting of acetaminophen, ibuprofen, pseudoephedrine, dextromethorphan, diphenhydramine, chlorpheniramine, calcium carbonate, magnesium hydroxide, magnesium carbonate, magnesium oxide, aluminum hydroxide, mixtures thereof, and pharmaceutically acceptable salts thereof.

12. (Original): An oral dosage form of claim 11, wherein the active agent is acetaminophen or ibuprofen.

13. (Original): An oral dosage form of claim 12, wherein the active agent is acetaminophen.

14. (Original): An oral dosage form of claim 12, wherein the active agent is ibuprofen.

15. (Currently Amended): A texture masking oral dosage form comprising:

(a) a unitary soft core comprising a plurality of acetaminophen particles having an average size of from about 150 μm to about 500 μm ~~greater than about 50 μm~~, a hydrocolloid, and water; and

(b) a brittle shell enveloping the soft core in an amount of from about 20% to about 50% of the total weight of the texture masking oral dosage form and a thickness of from about 500 μm to about 3000 μm, wherein the weight ratio of active agent to shell is from about 1.0:4 to about 1.0:9 in the texture masking oral dosage form.

16. (Currently Amended): A texture masking oral dosage form comprising:

(a) a unitary soft core comprising a plurality of ibuprofen particles having an average size of from about 150 μm to about 500 μm ~~greater than about 50 μm~~, a hydrocolloid, and water; and

(b) a brittle shell enveloping the soft core in an amount of from about 20% to about 50% of the total weight of the texture masking oral dosage form and a thickness of from about 500 μm to about 3000 μm, wherein the weight ratio of particles to shell is from about 1.0:4 to about 1.0:9 in the texture masking oral dosage form.

17. (Currently Amended): A texture masking oral dosage form comprising:

(a) a unitary soft core comprising a plurality of active agent particles having an average size of from about 150 μm to about 500 μm ~~greater than about 50 μm~~, a hydrocolloid, and water; and

(b) a brittle shell encasing the soft core in an amount of from about 20% to about 50% of the total weight of the texture masking oral dosage form and a thickness of from about 500 μm to about 3000 μm, wherein the weight ratio of active agent particles to shell is from about 1.0:0.5 to about 1.0:15 and wherein the soft core has a hardness of about 1 to about 8 kp/cm^2 in the texture masking oral dosage form.

18. (Previously Presented): An oral dosage form of claim 17, wherein the weight ratio of active agent particles to shell is from about 1.0:2 to about 1.0:12.

19. (Previously Presented): An oral dosage form of claim 18, wherein the weight ratio of active agent particles to shell is from about 1.0:4 to about 1.0:9.

20. (Previously Presented): An oral dosage form of claim 17, wherein the soft core is pectin based.

21. (Previously Presented): An oral dosage form of claim 17, wherein the soft core is gelatin based.

22. (Previously Presented): An oral dosage form of claim 17, wherein the active agent is selected from the group consisting of acetaminophen, ibuprofen, pseudoephedrine, dextromethorphan, diphenhydramine, chlorpheniramine, calcium carbonate, magnesium

hydroxide, magnesium carbonate, magnesium oxide, aluminum hydroxide, mixtures thereof, and pharmaceutically acceptable salts thereof.

23. (Previously Presented): An oral dosage form of claim 22, wherein the active agent is acetaminophen or ibuprofen.

24. (Previously Presented): An oral dosage form of claim 23, wherein the active agent is acetaminophen.

25. (Previously Presented): An oral dosage form of claim 23, wherein the active agent is ibuprofen.

26. (Withdrawn): A texture masking oral dosage form formed by the process comprising the steps of:

(a) compressing a plurality of active agent particles having an average size of greater than about 50 μm, a hydrocolloid, and water thereby forming a unitary soft core; and

(b) coating the soft core thereby encasing the soft core with a brittle shell, wherein the brittle shell is from about 20% to about 50% of the total weight of the texture masking oral dosage form and has a thickness of from about 500 μm to about 3000 μm, wherein the weight ratio of active agent particles to shell is from about 1.0:0.5 to about 1.0:15 in the texture masking oral dosage form, and

wherein the step of coating involves panning, dipping, or spraying.